Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR), a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets, announced that its Class A common stock and warrants will begin trading on the New York Stock Exchange today under the symbols “MIR” and “MIRW,” respectively. Management will participate in a closing bell ceremony at the New York Stock Exchange today, October 21, 2021, in celebration of the public listing.

“We are thrilled to embark upon our next chapter as a public company and to continue to lead the market in radiation solutions and services,” commented Thomas Logan, Chief Executive Officer of Mirion. “This transaction allows us to continue to execute on our strategic growth plans by expanding our product suite across the industrial technology and medical segments and further executing on our robust acquisition pipeline. We are also very pleased to welcome Larry Kingsley to our Board as Chairman, who brings with him a proven track record of operational success and driving value creation for shareholders. I would like to thank the entire Mirion team, as well as our partners Larry and Goldman Sachs, for their support throughout this process, and we look forward to entering this next phase for our business together.”

Larry Kingsley, former CEO of Pall Corporation and IDEX Corporation, will assume the role of Chairman of the Company. Mirion will continue to be led by 20-year industry veteran and company founder, Mr. Logan.

Larry Kingsley, Chairman of Mirion, said, “I am very pleased to be joining Tom and the Mirion team, who have done an excellent job building a global company in good industries, with strong margin profiles and robust free cash flow generation. There is ample room ahead to drive margin expansion, execute on organic growth opportunities, and drive long-term shareholder value.”

Prior to the closing of the business combination, Mirion was majority owned by Charterhouse Capital Partners LLP (“Charterhouse”), one of the longest established private equity firms operating in Europe, which first invested in Mirion in 2015.

Chris Warren, Partner at Charterhouse, remarked, “Mirion’s robust growth in recent years is a testament to the dedication of the whole Mirion team. Having become the global leader in nuclear measurement and following its strategic expansion into medical and life sciences, Mirion is well positioned to capitalise on a wide range of additional growth opportunities. We look forward to seeing Mirion’s continued development and further accomplishments in years to come and wish Tom and his team the best of luck.”

Mirion is a global provider of products, services, and software that allows customers to safely leverage the power of ionizing radiation through critical applications in the medical, nuclear and defense markets, as well as laboratories, scientific research, analysis and exploration. Mirion generated $612 million in revenue for the fiscal year ended June 30, 2021, up 27.9% from the prior-year period, reflecting core industrial market growth and the continued success of key new product introductions in the medical field.

Goldman Sachs & Co. LLC acted as lead placement agent and exclusive financial advisor to GS Acquisition Holdings Corp II (“GSAH”). Lazard Ltd. and HSBC acted as financial advisors to Charterhouse and Mirion. Goldman Sachs Lending Partners LLC, Citigroup Global Markets Inc., Jefferies Finance LLC and JPMorgan Chase Bank, N.A. acted as joint lead arrangers and joint bookrunners for the debt financing in support of the transaction. Weil, Gotshal & Manges LLP acted as legal advisor to GSAH. Davis Polk & Wardwell LLP acted as legal advisor to Mirion and Freshfields Bruckhaus Deringer LLP acted as legal advisor to Charterhouse. Sullivan & Cromwell LLP acted as legal advisor to Goldman Sachs & Co. LLC as lead placement agent. Milbank LLP acted as legal advisor to Goldman Sachs Lending Partners LLC and Citigroup Global Markets Inc.

About Mirion
Mirion Technologies is a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Many of the company's end markets are characterized by the need to meet rigorous regulatory standards, design qualifications and operating requirements. Headquartered in Atlanta (GA – USA), Mirion employs around 2,500 people and operates in 13 countries. For more information, and for the latest news and content from Mirion, visit Mirion.com. Prior to the closing of the business combination, Mirion was majority owned by Charterhouse Capital Partners LLP.

About GSAH
GS Acquisition Holdings Corp II (NYSE: GSAH) is a special purpose acquisition company formed for the purpose of effecting a merger, stock purchase or similar business combination with one or more businesses. The company is sponsored by an affiliate of The Goldman Sachs Group, Inc. In June 2020, GSAH completed its initial public offering, raising $750 million from investors.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding trading of Mirion’s securities on the New York Stock Exchange, Mirion’s market leadership and the ability of Mirion to drive margin expansion and long-term shareholder value, execute on its growth plans and expand its product suite, and potential acquisitions. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this press release, words such as “pro forma,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When Mirion discusses its strategies or plans, it is making projections, forecasts and forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to Mirion’s management.

These forward-looking statements involve significant risk and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Mirion’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the ability to maintain the listing of Mirion’s securities on the New York Stock Exchange; (2) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (3) costs related to the business combination; (4) changes in applicable laws or regulations; (5) the possibility that Mirion may be adversely affected by other economic, business, and/or competitive factors; (6) the outcome of any legal proceedings that have been or may in the future be instituted against Mirion or any of their respective directors or officers; (7) the failure to realize anticipated pro forma results or projections and underlying assumptions; (8) future global, regional or local political, market and social conditions, including due to the COVID-19 pandemic; and (9) other risks and uncertainties indicated from time to time in the definitive proxy statement/prospectus of Mirion, including those under “Risk Factors” therein, and other documents filed or to be filed with the Securities and Exchange Commission (“SEC”) by Mirion.

Forward-looking statements included in this release speak only as of the date of this release. Mirion does not undertake any obligation to update its forward-looking statements to reflect events or circumstances after the date of this release. Additional risks and uncertainties are identified and discussed in Mirion’s reports filed with the SEC and available at the SEC’s website at http://www.sec.gov.

This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.